Alan Meds vs MyFastRx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
MyFastRx
Best for Cash-pay patients comfortable with 12-month upfront billing for the lowest compounded-GLP-1 monthly rate.Starting at $99/mo
Side-by-Side Comparison
| Feature | Alan Meds | MyFastRx |
|---|---|---|
| Overall Score | ✓7.7/10 | 7.0/10 |
| Starting Price | $99/mo | $99/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.5 ★ /5 |
| Features | 5 features | ✓8 features |
| States Available | ✓46 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
MyFastRx
Pros
- ✓Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
- ✓LegitScript ID (24730) traceable
- ✓All doses same price (no escalation cost)
- ✓Promo first-month discount lowers trial barrier
Cons
- ✗States-served list not disclosed — only 'multiple states' / 'licensed U.S. providers'
- ✗Corporate address and medical director not published
- ✗Pharmacy partner not named — only 'state-licensed pharmacies'
- ✗Cash-pay only (no insurance billing)
- ✗Bundle savings require large upfront commitment (12 months billed)
Our Verdict
Alan Meds edges out MyFastRx with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. MyFastRx remains a solid alternative, especially if you're looking for Cash-pay patients comfortable with 12-month upfront billing for the lowest compounded-GLP-1 monthly rate..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.